Effects of antihypertensives on arterial responses associated with obstructive sleep apneas
Xu Zhong1, Yi Xiao, Robert C Basner
1Department of Pulmonary Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China. zhongxupumc@yahoo.com.cn
Background:
Many patients with obstructive sleep apnea syndrome (OSAS) have complicated with hypertension and may be prescribed with antihypertension medications to control their blood pressure. But whether antihypertension medications can also decrease arterial stiffness or control the blood pressure increasing following obstructive events is not well described. This study aimed to investigate whether antihypertensive medications can ameliorate the changes in arterial stiffness and blood pressure associated with OSA.
Methods:
Sixty-one OSAS patients [13 women, 48 men, mean age (53.4 +/- 12.3) years], 26 normotensive patients (N), 7 hypertensive patients on no antihypertension medications (H), and 28 hypertensive patients on various combination antihypertension therapy (HM), were prospectively diagnosed with standard nocturnal polysomnography. Beat-to-beat blood pressure was continuously recorded from the radial artery by applanation tonometry during baseline sleep. As a measure of arterial stiffness, arterial augmentation index (AAI) was calculated as the ratio of augmented systolic blood pressure (SBP) to pulse pressure and expressed as a percentage for the following conditions: awakening, the first 10 ("early apnea") and last 10 ("late apnea") cardiac cycles of obstructive events (apnea or hypopnea), and the first 15 cardiac cycles following event termination ("post apnea") for all events with nadir O2 saturation
Results:
Systolic blood pressure (SBP) post-apnea [(142.74 +/- 13.06) mmHg (N), (137.06 +/- 26.56) mmHg (H), (136.94 +/- 14.1) mmHg (HM)] was significantly increased from awakening [(135.76 +/- 14.76) mmHg (N), (135.58 +/- 23.17) mmHg (H), (129.77 +/- 14.00) mmHg (HM)], early apnea [(130.53 +/- 12.65) mmHg (N), (124.47 +/- 24.97) mmHg (H), (126.04 +/- 13.12) mmHg (HM)], and late apnea [(129.8 +/- 12.68) mmHg (N), (124.78 +/- 25.15) mmHg (H), (124.48 +/- 13.82) mmHg (HM)] respectively (P < 0.001, repeated measures ANOVA). AAI was significantly increased for the N group (P < 0.001) from awakening to late apnea [(10.45 +/- 2.62)% vs (14.43 +/- 3.21)%] and from early apnea to late apnea [(10.61 +/- 2.34)% vs (14.43 +/- 3.21)%], and also for H group (P < 0.05) from awakening to late apnea [(11.23 +/- 3.87)% vs (16.32 +/- 8.02)%] and from early apnea to late apnea [(11.75 +/- 3.79)% vs (16.32 +/- 8.02)%]. Meanwhile, no significant differences in AAI among awakening, early apnea, late apnea, and post-apnea conditions were found in HM group.
Conclusions:
The current data demonstrate that systemic blood pressure increases significantly during the post-apneic phase of OSAS, compared with that during awakening and intra-apnea phases even with the use of combined antihypertensive therapy which could normalize BP during awakening in the hypertensive patients. However, increases in arterial stiffness during obstructive events could be ameliorated by combined antihypertension medications.
Related Concept Videos
Sleep Apnea
The condition is more prevalent among...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

